DOCSLIB.ORG

Moclobemide and Selegeline in the Treatment of Depression In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Moclobemide and Selegeline in the Treatment of Depression In J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.63.4.547 on 1 October 1997. Downloaded from Journal of Neurology, Neurosurgery, and Psychiatry 1997;63:547–558 547 Before treatment tients in this study was too small to give 35 robust answers in this respect. LETTERS TO After treatment Tyramine restriction during combined 30 MAO inhibition is inconvenient. But if THE EDITOR further studies confirm the additional efficacy 25 of combined MAO-A and MAO-B inhibi- tion, then this hindrance is justifiable. 20 * ERNSTNHJANSEN STEUR Moclobemide and selegeline in the 15 Department of Neurology LEO A P BALLERING treatment of depression in Parkinson’s 10 disease Department of Clinical Chemistry, MST Hospital, 5 Enschede, The Netherlands Monoamine oxidase (MAO) is the predomi- Hamilton depression score Correspondence to: Dr ENHJansenSteur, nant enzyme implied in the catabolism of the 0 Department of Neurology, Hospital Medisch Spec- Moclobemide Moclobemide trum Twente, PO Box 50.000, 7500 KA, Enschede, monoamines dopamine, noradrenaline, and and 1 The Netherlands. Telephone +31 53 4872000; fax serotonin. Dopamine is a substrate for both selegeline +31 53 4873100. isoforms of MAO: the extraneuronal MAO-B; and MAO-A which is found both extraneuro- Intensity of depression before and after treatment 2 with moclobemide or moclobemide and 1 DaPrada M, Zürcher G, Wüthrich I, Haefely nally and intraneuronally. Intraneuronal selegeline. MAO-A is active for dopamine, noradrena- WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J line, and serotonin, which have a paramount Neural Transm 1988;8(suppl 26):31–56. influence in the pathogenesis of depression. 1.8 hours, and in the MOSES group with 5.2 2 Youdim MBH, Riederer P. Dopamine metabo- The combination of MAO-A and MAO-B hours. This diVerence was not significant lism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition results in a strong increase of both (P=0.671, two sample t test). Baseline clinicians’ rating of depression inhibition. JNeuralTransm1993;91:181–96. dopamine, noradrenaline, and serotonin. De- 3 Lees AJ. on behalf of the Parkinson’s Disease pression is the most frequent psychopatho- (HDRS) was not diVerent between the two Research Group of the United Kingdom. logical finding in Parkinson’s disease. groups. After six weeks, however, the im- Comparison of therapeutic eVects and provement of depression in the MO group mortality data of levodopa and levodopa com- In this study we compared moclobemide was significantly less than in the MOSES bined with selegeline in patients with early, monotherapy with combined therapy with mild Parkinson’s disease. BMJ 1995;311: group (P=0.0029; two sample test, figure). moclobemide and selegeline, under tyramine t 1602–7. The main phenomenology of the depres- 4 Sieradzan K, Channon S, Ramponi C, Stern restriction. sive illness was a depressed mood with GM, Lees AJ, Youdim MBH. The therapeutic Ten patients with idiopathic Parkinson’s potential of moclobemide, a selective monoam- psychomotor retardation. disease of two to 15 years in duration ine oxidase A inhibitor in Parkinson’s disease. J The scores of MMSE disclosed no diVer- 1995; (suppl 2):51S– contributed to the study. The actions of Clin Psychopharmacol 15 ences in both groups at entry in the study. At 59S. moclobemide and selegeline were described the end of the study the score was unchanged 5 Takats A, Tarczy N, Simo M, Szombathely E, in the informed consent. Inclusion criteria Bodrogi A, Karpati R. Moclobemide/aurix in the MO group, and there was a slight but were Parkinson’s disease disability Hoehn treatment in Parkinson’s disease with depres- significant increase of MMSE score in the sion. New Trends in Clinical Neuropharmacology and Yahr stages II-IV, major depression using MOSES group (P=0.0479; two sample t 1994;8:260. 6 Knegtering H, Eyck M, Huysman P. EVects of DSM III.R criteria, mini mental state test). examination (MMSE) score of 21 or above, antidepressants on cognitive functioning of There was no increase in blood pressure. In elderly patients. Drugs Aging 1994;5:192–9. and self recorded “on-oV” patient diaries. A both groups one patient reported sympto- 7 Roth M, Mountjoy CQ, Amrein R. Mo- cut-oV point of 21 on MMSE score was used matic hypotension. clobemide in elderly patients with cognitive to allow study of patients with Parkinson’s decline and depression. Br J Psychiatry 1996; The therapeutic potential of selective inhi- 168:145–57. disease without substantial cognitive impair- bition of MAO B with selegeline in Parkin- ment. All patients had been on optimal and son’s disease has been documented for many stable dosage of antiparkinson medication years, with a clear capacity to postpone the Brain biopsy and patients with atypical during the previous three months. need for levodopa in early Parkinson’s presentations of sporadic Creutzfeldt- The present major depression had a dura- disease. The neuroprotective properties of Jakob disease http://jnnp.bmj.com/ tion of three to 15 months. Antidepressant selegeline are controversial or inconclusive.3 medical treatment had not been initiated in Selective MAO-A inhibition in Parkinson’s Brain biopsy, or meningeal biopsy, or both are any of these 10 patients before entering this disease has not been examined in detail. Sier- performed to exclude treatable neuropatho- study. adzan et al4 found a mild symptomatic eVect logical disorders in a range of cases in which Moclobemide (600 mg) with or without of moclobemide in non-depressed patients clinical, neuroradiological, and other investi- selegeline (10 mg) was administered during with Parkinson’s disease. Takats et al5 re- gative findings fail to define a diagnosis. The the six week study period. Regular antipar- ported an antidepressant eVect of mo- description of a new clinicopathological vari- kinson medication was kept unchanged. Fol- clobemide in depressed patients with Parkin- ant of Creutzfeldt-Jakob disease shows that stein’s mini mental state examination score, son’s disease. Moclobemide lacks some cases of this rare disease may present on September 26, 2021 by guest. Protected copyright. patients’ “on-oV” diaries during five days, anticholinergic and hepatotoxic eVects, and is atypically and the diagnosis in life may and the Hamilton depression rating scale even able to antagonise the cognitive impair- depend on brain biopsy.1 Although the (HDRS) for depression were assessed one ment resulting from cholinergic blockade.6 Department of Health guidelines on neuro- week before and after six weeks of treatment; The present study confirms the antidepres- surgical and ophthalmic operative procedures MMSE and HDRS were scored in the “on” sant eVects of moclobemide in depressed minimise any risk of subsequent iatrogenic state of motor response to levodopa. Patients patients with Parkinson’s disease. The combi- transmission 6% of cases of Creutzfeldt- were randomly assigned to moclobemide nation of moclobemide and selegeline, how- Jakob disease present with a stroke-like disor- monotherapy or to the combination of ever, did have a more pronounced eYcacy on der with equivocal clinical, electrophysiologi- moclobemide and selegeline. These two mood and cognitive performances. Increased cal, or neuroradiological support for the treatment groups are further referred to as concentrations of the monoamines by com- diagnosis.2 There is, therefore, the potential the MO group and the MOSES group. bined MAO inhibition is a plausible reason danger of iatrogenic transmission of Bradykinesia and start hesitation improved for the superior eYcacy of moclobemide/ Creutzfeldt-Jakob disease after inadvertent in six patients, one patient in the MO group selegeline treatment over monotherapy with brain biopsy of such patients. The Depart- and all patients in the MOSES group. Brady- moclobemide in depressed patients with Par- ment of Clinical Neurosciences in Edinburgh kinesia deteriorated in one patient (MO kinson’s disease. therefore, created a dedicated set of neuro- group). Tremor increased in four patients, The eVect of combined MAO inhibition on surgical instruments designated purely for one in the MO group and three in the the MMSE scores was significant. The influ- open brain biopsy. These instruments were MOSES group. ence of MAO-A and MAO-B inhibition on repacked and sterilised after each biopsy. There were no significant diVerences for cognitive functions is becoming of increasing This precaution was vindicated by the the percentage “on” hours per day between importance in recent years. The cognitive following case. the MO group and the MOSES group at improvement with moclobemide is parallel A 65 year old man presented with a history entry and at the end of study. Waking hours to, but independent from, the establishing of of headache for some months followed by the spent “on” increased in the MO group with antidepressant eVects.7 The number of pa- acute onset of expressive dysphasia and right J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.63.4.547 on 1 October 1997. Downloaded from 548 Letters, Correspondence, Correction, Book reviews hemiparesis. There was subsequently some 1 Will GR, Ironside JW, Zeidler M, et al.Anew Transient global amnesia provides a model progression in the weakness and he was varient of Creutzfeld-Jakob disease in the UK. of severe, yet transient, amnesia.6–8 Findings Lancet 1996;347:921–5. admitted to hospital for investigation. There 2 McNaughton H, Will R. Creutzfeldt-Jakob dis- during transient global amnesia have con- was a history of previous stroke in June 1989 ease presenting as stroke. Analysis of 30 cases. firmed that there is a profound loss of antero- presenting with expressive dysphasia and Ann Neurol 1994;36:313. grade episodic memory for both verbal and 3 Hayward PAR, Bell JE, Ironside JW. Prion pro- non-verbal material, together with a variable hemiplegia which recovered completely over tein immunocytochemistry.
Load more

Recommended publications
  • Surgical Management of Parkinson's Disease
    SEMINAR PAPER DTM Chan Surgical management of Parkinson’s VCT Mok WS Poon disease: a critical review KN Hung XL Zhu ○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○ !"#$%&'()*+, Parkinson’s disease is a progressive disabling movement disorder that is characterised by three cardinal symptoms: resting tremor, rigidity, and bradykinesia. Before the availability of effective medical treatment with levodopa and stereotactic neurosurgery, the objective of surgical management was to alleviate symptoms such as tremor at the expense of motor deficits. Levodopa was the first effective medical treatment for Parkinson’s disease, and surgical treatment such as stereotactic thalamo- tomy became obsolete. After one decade of levodopa therapy, however, drug-induced dyskinesia had become a source of additional disability not amenable to medical treatment. Renewed interest in stereotactic functional neurosurgery to manage Parkinson’s disease has been seen since the 1980s. Local experience of deep-brain stimulation is presented and discussed in this paper. Deep-brain stimulation of the subthalamic nucleus is an effective treatment for advanced Parkinson’s disease, although evidence from randomised control trials is lacking. !"#$%&'()*+,-!./01$23456789:; Key words: !"#$%&'()*+,-./01'23456789:;< Electric stimulation; !"#$%&'()*+,-./01(23#45+6789: Globus pallidus/surgery; Parkinson disease; !"#$%&'()*+,-./012345678'9:;< Stereotactic techniques; !"#$%&'()*%+,-./0123)456789:; Subthalamic nuclei/surgery; !"#$%&'()*+,-.1980 !"#$%&'()* Thalamus/surgery !"#$%&'()*+,-./0123456789:;<=
    [Show full text]
  • Multiplex Families with Multiple System Atrophy
    ORIGINAL CONTRIBUTION Multiplex Families With Multiple System Atrophy Kenju Hara, MD, PhD; Yoshio Momose, MD, PhD; Susumu Tokiguchi, MD, PhD; Mitsuteru Shimohata, MD, PhD; Kenshi Terajima, MD, PhD; Osamu Onodera, MD, PhD; Akiyoshi Kakita, MD, PhD; Mitsunori Yamada, MD, PhD; Hitoshi Takahashi, MD, PhD; Motoyuki Hirasawa, MD, PhD; Yoshikuni Mizuno, MD, PhD; Katsuhisa Ogata, MD, PhD; Jun Goto, MD, PhD; Ichiro Kanazawa, MD, PhD; Masatoyo Nishizawa, MD, PhD; Shoji Tsuji, MD, PhD Background: Multiple system atrophy (MSA) has Results: Consanguineous marriage was observed in 1 been considered a sporadic disease, without patterns of of 4 families. Among 8 patients, 1 had definite MSA, 5 inheritance. had probable MSA, and 2 had possible MSA. The most frequent phenotype was MSA with predominant parkin- Objective: To describe the clinical features of 4 multi- sonism, observed in 5 patients. Six patients showed pon- plex families with MSA, including clinical genetic tine atrophy with cross sign or slitlike signal change at aspects. the posterolateral putaminal margin or both on brain mag- netic resonance imaging. Possibilities of hereditary atax- Design: Clinical and genetic study. ias, including SCA1 (ataxin 1, ATXN1), SCA2 (ATXN2), Machado-Joseph disease/SCA3 (ATXN1), SCA6 (ATXN1), Setting: Four departments of neurology in Japan. SCA7 (ATXN7), SCA12 (protein phosphatase 2, regula- tory subunit B, ␤ isoform; PP2R2B), SCA17 (TATA box Patients: Eight patients in 4 families with parkinson- binding protein, TBP) and DRPLA (atrophin 1; ATN1), ism, cerebellar ataxia, and autonomic failure with age at ␣ onset ranging from 58 to 72 years. Two siblings in each were excluded, and no mutations in the -synuclein gene family were affected with these conditions.
    [Show full text]
  • Understanding Icd-10-Cm and Icd-10-Pcs 3Rd Edition Download Free
    UNDERSTANDING ICD-10-CM AND ICD-10-PCS 3RD EDITION DOWNLOAD FREE Mary Jo Bowie | 9781305446410 | | | | | International Classification of Diseases, (ICD-10-CM/PCS) Transition - Background Palmer B. Manual placenta removal. A: Understanding ICD-10-CM and ICD-10-PCS 3rd edition International Classification of Diseases ICD is a common framework and language to report, compile, use and compare health information. Psychoanalysis Adlerian therapy Analytical therapy Mentalization-based treatment Transference focused psychotherapy. Hysteroscopy Vacuum aspiration. Every code begins with an alpha character, which is indicative of the chapter to which the code is classified. Search Compliance Understanding BC, resilience standards and how to comply Follow these nine steps to first identify relevant business continuity and resilience standards and, second, launch a successful While many coders use ICD lookup software to help them, referring to an ICD code book is invaluable to build an understanding of the classification system. Pregnancy test Leopold's maneuvers Prenatal testing. Endoscopy : Colonoscopy Anoscopy Capsule endoscopy Enteroscopy Proctoscopy Sigmoidoscopy Abdominal ultrasonography Defecography Double-contrast barium enema Endoanal ultrasound Enteroclysis Lower gastrointestinal series Small-bowel follow-through Transrectal ultrasonography Virtual colonoscopy. Psychosurgery Lobotomy Bilateral cingulotomy Multiple subpial transection Hemispherectomy Corpus callosotomy Anterior temporal lobectomy. While codes in sections are structured similarly to the Medical and Surgical section, there are a few exceptions. Send Feedback Do you have Understanding ICD-10-CM and ICD-10-PCS 3rd edition on the new website? Help Learn to edit Community portal Recent changes Upload file. D Radiation oncology. Stem cell transplantation Hematopoietic stem cell transplantation. The primary distinctions are:. Palmer Joseph C.
    [Show full text]
  • Pallidotomy and Thalamotomy
    Pallidotomy and Thalamotomy Vancouver General Hospital 899 West 12th Avenue Vancouver BC V5Z 1M9 Tel: 604-875-4111 This booklet will provide information about the following Preparing for Surgey surgical procedures: Pallidotomy and Thalamotomy. Before Admission to Hospital What is a Pallidotomy? 1) Anticoagulants and other medications that thin your A pallidotomy is an operation for Parkinson’s disease blood such as Aspirin, Coumadin (Warfarin), Lovenox where a small lesion is made in the globus pallidum (an (Enoxaparin), Ticlid (Ticlopidine), Plavix (Clopidogrel) area of the brain involved with motion control). The lesion and Ginkgo must be discontinued 2 weeks before your is made by an electrode placed in the brain through a small surgery. Pradaxa (Dabigatran), Xarelto (Rivaroxaban) opening in the skull. The beneficial effects are seen on and Eliquis (Apixaban) must be discontinued 5 days the opposite side of the body, i.e. a lesion on the left side before your surgery. of your brain will help to control movement on the right 2) Since you will be having a MRI, it is important to inform side of your body. Pallidotomy will help reduce dyskinesia your neurosurgeon if you are claustrophobic, have metal (medication induced writhing), and will also improve fragments in your eye or have a pacemaker. bradykinesia (slowness). Admission to Hospital Risks Your surgeon’s office will contact you the day before your Risks include a rare chance of death (0.2%) and a low scheduled surgery to confirm the time to report to the Jim chance (7%) of weakness or blindness on the opposite side Pattison Pavilion Admitting Department.
    [Show full text]
  • Neurocognitive and Psychosocial Correlates of Ventroposterolateral Pallidotomy Surgery in Parkinson's Disease
    Neurocognitive and psychosocial correlates of ventroposterolateral pallidotomy surgery in Parkinson's disease Henry J. Riordan, Ph.D., Laura A. Flashman, Ph.D., and David W. Roberts, M.D. Department of Psychiatry and Section of Neurosurgery, Dartmouth Medical School, Dartmouth­Hitchcock Medical Center, Lebanon, New Hampshire The purpose of this study was to characterize the neuropsychological and psychosocial profile of patients with Parkinson's disease before and after they underwent unilateral left or right pallidotomy, to assess specific cognitive and personality changes caused by lesioning the globus pallidus, and to predict favorable surgical outcome based on these measures. Eighteen patients underwent comprehensive neuropsychological assessment before and after left-sided pallidotomy (10 patients) or right-sided pallidotomy (eight patients). The findings support the presence of frontosubcortical cognitive dysfunction in all patients at baseline and a specific pattern of cognitive impairment following surgery, with side of lesion being an important predictor of pattern and degree of decline. Specifically, patients who underwent left-sided pallidotomy experienced a mild decline on measures of verbal learning and memory, phonemic and semantic verbal fluency, and cognitive flexibility. Patients who underwent right-sided pallidotomy exhibited a similar decline in verbal learning and cognitive flexibility, as well as a decline in visuospatial construction abilities; however, this group also exhibited enhanced performance on a delayed facial memory measure. Lesioning the globus pallidus may interfere with larger cognitive circuits needed for processing executive information with disruption of the dominant hemisphere circuit, resulting in greater deficits in verbal information processing. The left-sided pallidotomy group also reported fewer symptoms of depression and anxiety following surgery.
    [Show full text]
  • Pallidotomy: Effective and Safe in Relieving Parkinson's Disease Rigidity
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Pakistan Journal Of Neurological Surgery ORIGINAL ARTICLE Pallidotomy: Effective and Safe in Relieving Parkinson’s Disease Rigidity NABEEL CHOUDHARY, TALHA ABBASS, OMAIR AFZAL Khalid Mahmood Department of Neurosurgery, Lahore General Hospital, Lahore ABSTRACT Introduction: Parkinson's Disease (PD) is a progressive neurological disorder caused by a loss of pigmented dopaminergic neurons of the substantia nigra pars compacta. The major manifestations of the disease consist of resting tremor, rigidity, bradykinesia and gait disturbances. Before the advent of Levodopa surgery was main stay of treatment of PD. Medical therapy is still the mainstay of treatment for Parkinson's diseasebut its prolonged use results in side effects like drug induced dyskinesia. In 1952 Dr. Lars Leksell introduced Pallidotomy that was successful in relieving many Parkinsonian symptoms in patients. Later on thalamotomy became widely accepted, replacing pallidotomy as the surgical treatment of choice for Parkinson's Disease. Thalamotomy had an excellent effect on the tremor, was not quite as effective at reducing rigidity rather bradykinesia was often aggravated by the procedure. Objective: Effectiveness of Pallidotomy in rigidity in medically refractory Parkinson’s disease and its complications. Study Design: Descriptive prospective case series. Setting of study: Department of Neurosurgery, Lahore General Hospital, Lahore. Duration: June 2013 to April 2016. Materials and Methods: Patients of Parkinson’s disease with predominant component of muscular rigidity despite maximum medical therapy admitted through outdoor department. Detailed history and physical exami- nation was done. Grading of muscular rigidity was done by applying UPDRS score Rigidity part 22.
    [Show full text]
  • Study Guide Medical Terminology by Thea Liza Batan About the Author
    Study Guide Medical Terminology By Thea Liza Batan About the Author Thea Liza Batan earned a Master of Science in Nursing Administration in 2007 from Xavier University in Cincinnati, Ohio. She has worked as a staff nurse, nurse instructor, and level department head. She currently works as a simulation coordinator and a free- lance writer specializing in nursing and healthcare. All terms mentioned in this text that are known to be trademarks or service marks have been appropriately capitalized. Use of a term in this text shouldn’t be regarded as affecting the validity of any trademark or service mark. Copyright © 2017 by Penn Foster, Inc. All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the copyright owner. Requests for permission to make copies of any part of the work should be mailed to Copyright Permissions, Penn Foster, 925 Oak Street, Scranton, Pennsylvania 18515. Printed in the United States of America CONTENTS INSTRUCTIONS 1 READING ASSIGNMENTS 3 LESSON 1: THE FUNDAMENTALS OF MEDICAL TERMINOLOGY 5 LESSON 2: DIAGNOSIS, INTERVENTION, AND HUMAN BODY TERMS 28 LESSON 3: MUSCULOSKELETAL, CIRCULATORY, AND RESPIRATORY SYSTEM TERMS 44 LESSON 4: DIGESTIVE, URINARY, AND REPRODUCTIVE SYSTEM TERMS 69 LESSON 5: INTEGUMENTARY, NERVOUS, AND ENDOCRINE S YSTEM TERMS 96 SELF-CHECK ANSWERS 134 © PENN FOSTER, INC. 2017 MEDICAL TERMINOLOGY PAGE III Contents INSTRUCTIONS INTRODUCTION Welcome to your course on medical terminology. You’re taking this course because you’re most likely interested in pursuing a health and science career, which entails ­proficiency­in­communicating­with­healthcare­professionals­such­as­physicians,­nurses,­ or dentists.
    [Show full text]
  • A Review on Parkinson's Disease Treatment
    Lee et al. Neuroimmunol Neuroinflammation 2021;8:[Online First] Neuroimmunology DOI: 10.20517/2347-8659.2020.58 and Neuroinflammation Review Open Access A review on Parkinson’s disease treatment Tori K. Lee, Eva L. Yankee Department of Biology, Pacific Union College, Angwin, CA 94508, USA. Correspondence to: Tori K. Lee, Department of Biology, Pacific Union College, 1 Angwin Ave, Angwin, CA 94508, USA. E-mail: [email protected] How to cite this article: Lee TK, Yankee EL. A review on Parkinson’s disease treatment. Neuroimmunol Neuroinflammation 2021;8:[Online First]. http://dx.doi.org/10.20517/2347-8659.2020.58 Received: 1 Oct 2020 First Decision: 1 Dec 2020 Revised: 15 Dec 2020 Accepted: 24 Dec 2020 Available online: 25 Jan 2021 Academic Editors: Athanassios P. Kyritsis, Backil Sung Copy Editor: Monica Wang Production Editor: Jing Yu Abstract Parkinson’s disease (PD) is a neurodegenerative illness and has a common onset between the ages of 55 and 65 years. There is progressive development of both motor and non-motor symptoms, greatly affecting one’s overall quality of life. While there is no cure, various treatments have been developed to help manage the symptoms of PD. Management of PD is a growing field and targets new treatment methods, as well as improvements to old ones. Pharmacological, surgical, and therapeutic treatments have allowed physicians to treat not only the main motor symptoms of PD, but target patient-specific problems as they arise. This review discusses both the established and new possibilities for PD treatment that can provide patient-specific care and mitigate side effects for common treatments.
    [Show full text]
  • Efficacy of Rhythmic Auditory Stimulation on Ataxia and Functional Dependence Post- Cerebellar Stroke" (2020)
    Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale School of Medicine Physician Associate Program Theses School of Medicine 5-22-2020 Efficacy of Rhythmicudit A ory Stimulation on Ataxia and Functional Dependence Post-Cerebellar Stroke Kaitlin Fitzgerald Yale Physician Associate Program, [email protected] Follow this and additional works at: https://elischolar.library.yale.edu/ysmpa_theses Recommended Citation Fitzgerald, Kaitlin, "Efficacy of Rhythmic Auditory Stimulation on Ataxia and Functional Dependence Post- Cerebellar Stroke" (2020). Yale School of Medicine Physician Associate Program Theses. 13. https://elischolar.library.yale.edu/ysmpa_theses/13 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale School of Medicine Physician Associate Program Theses by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. EFFICACY OF RHYTHMIC AUDITORY STIMULATION ON ATAXIA AND FUNCTIONAL DEPENDENCE POST-CEREBELLAR STROKE A Thesis Presented to The Faculty of the School of Medicine Yale University In Candidacy for the degree of Master of Medical Science May 2020 Kaitlin Fitzgerald, PA-SII Dr. Diana Richardson, MD Class of 2020 Assistant Clinical Professor Yale Physician Associate Program. Yale School of Medicine, Neurology i Table of Contents ABSTRACT
    [Show full text]
  • Neurologic Outcomes in Friedreich Ataxia: Study of a Single-Site Cohort E415
    Volume 6, Number 3, June 2020 Neurology.org/NG A peer-reviewed clinical and translational neurology open access journal ARTICLE Neurologic outcomes in Friedreich ataxia: Study of a single-site cohort e415 ARTICLE Prevalence of RFC1-mediated spinocerebellar ataxia in a North American ataxia cohort e440 ARTICLE Mutations in the m-AAA proteases AFG3L2 and SPG7 are causing isolated dominant optic atrophy e428 ARTICLE Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy revisited: Genotype-phenotype correlations of all published cases e434 Academy Officers Neurology® is a registered trademark of the American Academy of Neurology (registration valid in the United States). James C. Stevens, MD, FAAN, President Neurology® Genetics (eISSN 2376-7839) is an open access journal published Orly Avitzur, MD, MBA, FAAN, President Elect online for the American Academy of Neurology, 201 Chicago Avenue, Ann H. Tilton, MD, FAAN, Vice President Minneapolis, MN 55415, by Wolters Kluwer Health, Inc. at 14700 Citicorp Drive, Bldg. 3, Hagerstown, MD 21742. Business offices are located at Two Carlayne E. Jackson, MD, FAAN, Secretary Commerce Square, 2001 Market Street, Philadelphia, PA 19103. Production offices are located at 351 West Camden Street, Baltimore, MD 21201-2436. Janis M. Miyasaki, MD, MEd, FRCPC, FAAN, Treasurer © 2020 American Academy of Neurology. Ralph L. Sacco, MD, MS, FAAN, Past President Neurology® Genetics is an official journal of the American Academy of Neurology. Journal website: Neurology.org/ng, AAN website: AAN.com CEO, American Academy of Neurology Copyright and Permission Information: Please go to the journal website (www.neurology.org/ng) and click the Permissions tab for the relevant Mary E.
    [Show full text]
  • Movement Disorders in the Elderly
    MOVEMENT DISORDERS IN THE ELDERLY Eugene C. Lai, M.D., Ph.D. Michael E. DeBakey VA Medical Center Baylor College of Medicine Houston, Texas MOVEMENT DISORDERS Neurologic dysfunctions in which there is either a paucity of voluntary and automatic movements (HYPOKINESIA) or an excess of movement (HYPERKINESIA) or uncontrolled movements (DYSKINESIA) typically unassociated with weakness or spasticity HYPOKINESIAS • Parkinson‟s disease • Secondary Parkinsonism • Parkinson‟s plus syndromes HYPERKINESIAS • Akathisia • Hemifacial spasm • Athetosis • Myoclonus • Ballism • Restless leg syndrome • Chorea • Tics • Dystonia • Tremor COMMON MOVEMENT DISORDERS IN THE ELDERLY • Parkinsonism • Tremor • Gait disorder • Restless leg syndrome • Drug-induced syndrome PARKINSONISM • Parkinson‟s disease • Secondary parkinsonism • Drug-induced parkinsonism • Vascular parkinsonism • Parkinson‟s plus syndromes • Multiple system atrophy • Progressive supranuclear palsy PARKINSON’S DISEASE PARKINSON’S DISEASE Classical Clinical Features • Resting Tremor • Cogwheel Rigidity • Bradykinesia • Postural Instability PARKINSON’S DISEASE Associated Clinical Features • Micrographia • Hypophonia • Hypomimia • Shuffling gait / festination • Drooling • Dysphagia NON-MOTOR COMPLICATIONS IN PARKINSON’S DISEASE • Sleep disturbances • Autonomic dysfunctions • Sensory phenomena • Neuropsychiatric manifestations • Cognitive impairment PARKINSON’S DISEASE General Considerations • The second most common progressive neurodegenerative disorder • The most common neurodegenerative movement
    [Show full text]
  • Pseudoparkinsonism: a Review of a Common Nonparkinsonian Hypokinetic Movement Disorder
    Vol.2, No.4, 108-112 (2013) Advances in Parkinson’s Disease http://dx.doi.org/10.4236/apd.2013.24020 Pseudoparkinsonism: A review of a common nonparkinsonian hypokinetic movement disorder Roger Kurlan*, Marcie L. Rabin Atlantic Neuroscience Institute, Overlook Medical Center, Summit, USA; *Corresponding Author: [email protected] Received 16 September 2013; revised 16 October 2013; accepted 24 October 2013 Copyright © 2013 Roger Kurlan, Marcie L. Rabin. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT [2-4]. Over time, clinicians learned that a variety of entities This article reviews the syndrome pseudopark- besides neuroleptic drugs can similarly cause a clinical insonism, a movement disorder described in the picture resembling that of PD. The notion that a parkin- literature that resembles parkinsonism but dif- sonian syndrome could be caused by cerebrovascular fers qualitatively. Patients with this disorder disease became popularized in the 1980’s and 1990’s. have apraxic slowness, paratonic rigidity, frontal Some publications referred to the condition as “vascular gait disorder and elements of akinesia that, pseudoparkinsonism” [5,6], similar to the term used for taken together, may be mistaken for true park- neuroleptic drugs. Other articles, in contrast, used the insonism. Pseudoparkinsonism appears to be term “vascular parkinsonism” to describe features with a common and is most often due to Alzheimer’s vascular etiology that are reminiscent of, but distinct disease or vascular dementia. It seems that pa- from, those found in PD.
    [Show full text]